National Breast and Ovarian Cancer Centre (NBOCC)

HTG - Aromatase inhibitors adjuvant endocrine therapy post-menopausal receptor-positive early bc

Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer.

This document supplements guideline recommendation 19 about the use of tamoxifen for the management of post-menopausal women with hormone receptor-positive early breast cancer contained in the NBCC Clinical Practice Guidelines for the Management of Early Breast Cancer, 2nd edition, 2001 (page 9).